Baylor College of Medicine: Triggering Antiviral Immune Response in Certain Breast Cancers
January 16, 2021
January 16, 2021
HOUSTON, Texas, Jan. 16 (TNSRes) -- The Baylor College of Medicine issued the following news release:
Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body's immune response. A new study published in Cell shows that endogenous mis-spliced RNA in tumor cells mimics an RNA virus, leading tumor cells to self-destruct . . .
Researchers at Baylor College of Medicine have discovered how therapeutics targeting RNA splicing can activate antiviral immune pathways in triple negative breast cancers (TNBC) to trigger tumor cell death and signal the body's immune response. A new study published in Cell shows that endogenous mis-spliced RNA in tumor cells mimics an RNA virus, leading tumor cells to self-destruct . . .